

**Iowa Medicaid Pharmaceutical and Therapeutics Committee
Minutes**

Date: November 19, 2020

Chairperson: Mark Graber, M.D.

Erin Halverson, IME staff, assisted in running the meeting with the Chairperson due to the virtual format.

Time: 9:30 a.m. to 12:10 p.m.

Location: WebEx Teleconference (due to COVID-19)

Committee Members Present: Mark Graber, M.D.; Charles Wadle, D.O.; Carole Frier, D.O.; Heidi Price-Eastman, R.Ph.; Kevin de Regnier, D.O.; Bruce Alexander, Pharm.D.; Holly Randleman, Pharm.D.; and Kellen Ludvigson, Pharm.D.

Iowa DHS Staff Present: Susan Parker, Pharm.D., Pharmacy Consultant

Iowa Medicaid Enterprise (IME) Staff Present: Steve Liles, Pharm.D.; Lauren Biczak, D.O.; Erin Halverson, R.Ph.; Gina Kuebler, R.Ph.; Pam Smith, R.Ph.; and Melissa Biddle.

Managed Care Organization (MCO) Staff Present: Lisa Todd, Amerigroup Iowa; Emily Rogers, Iowa Total Care.

Chairperson Mark Graber called the meeting to order.

- I. Mark Graber asked that each committee and DHS and IME staff member introduce themselves to the public. Kevin de Regnier disclosed that he was on the speaker's bureau for Novo Nordisk, and would be abstaining from any votes on their products and competitor products due to the conflict of interest. The August 20, 2020, open session minutes were reviewed. Bruce Alexander made the motion to approve the minutes, and Kellen Ludvigson seconded. The motion passed with no objections.
- II. PDL and Drug Rebate Issues (Dr. Liles): This is the annual drug review for changes effective January 1, 2021, though there are not a lot of significant changes. The potential loss of rebates on Medication Assisted Treatment (MAT) medications due to a provision of the SUPPORT Act passed by Congress was discussed at the last meeting. However, since then, Congress has fixed the language in the SUPPORT Act, so states and the federal government can continue to receive the applicable rebates.
- III. PA Criteria/Pro-DUR Edits (Dr. Parker): Susan Parker reviewed the informational letters that had been sent out since the last P&T Meeting in August, all posted online at http://iowamedicaidpdl.com/informational_letters and http://iowamedicaidpos.com/latest_news. Providers received Informational Letter 2161-MC-FFS regarding PDL and PA and quantity limit changes resulting from the August P&T Meeting and March DUR Meeting recommendations. Some of the changes were held up because of COVID-19. Informational Letter 2163-MC-FFS was related to a payer sheet update for point-of-sale claims processing, related to the requirement to use the Quantity Prescribed field for Schedule II drugs. Informational Letter 2170-MC-FFS listed PA changes resulting from the August DUR recommendations. The committee also received copies of the letter sent to the Department of Human Services from the DUR Commission after their November meeting, which included ProDUR quantity limit recommendations for baclofen, Nurtec ODT, Reyvow, and Ubrelvy, as well as recommended criteria for: Acute Migraine Treatments; Pirlfenidone (Esbriet)/Nintedanib (Ofev); Adenosine Triphosphate-Citrate Lyase (ACL) Inhibitors; and Peanut Allergen Powder (Palforzia).

- IV. Legislation (Dr. Parker): Committee members were provided a copy of the email sent by CMS explaining the correction to the SUPPORT Act language regarding rebates on MAT drugs as Steve Liles explained above.
- V. IME Updates: There was nothing notable to report.
- VI. Public Comment: As this meeting was purely virtual, only written public comment was accepted. The committee members reviewed the received comments, which are posted at: <http://www.iowamedicaidpdl.com/public-comments>. They were also forwarded manufacturer comments as they were received via email prior to the meeting.

At 9:45, motion to go to closed session, as authorized by Iowa Code section 21.5(1)(a) of the Open Meetings Law to review and discuss those closed-session items listed on the meeting agenda - manufacturer price information, which are required or authorized to be kept confidential, was made by Kellen Ludvigson and seconded by Bruce Alexander. The motion passed with unanimous roll call approval. Open session resumed at 11:04.

- VII. PDL Discussion and Deliberation (Dr. Biczak): All subsequent recommendations (with numbering as provided on agenda attachment 3) were made to maximize cost savings to the program unless otherwise noted.
 - 1. Recommend to change Kitabis Pak to Preferred.
 - 2. Recommend to change Stiolto Respimat to Non-Preferred.
 - 3. Recommend to change Anoro Ellipta to Preferred.
 - 4. Recommend to change Spiriva Respimat to Preferred.
 - 5. Recommend to change Diclegis to Non-Preferred.
 - 6. Recommend to change Bonjesta to Preferred.
 - 7. Recommend to change Fasenra Auto-Injector to Preferred with Conditions.
 - 8. Recommend to change Taltz to Preferred with Conditions with a step through one preferred TNF.
 - 9. Recommend to change Cosentyx to Non-Preferred with Conditions.
 - 10. Recommend to change Abilify Maintena to Preferred Step 2.
 - 11. Recommend to change Nplate to Preferred with Conditions.
 - 12. Recommend to change Nurtec to Preferred with Conditions.
 - 13. Recommend to change Ajoyv to Preferred with Conditions.
 - 14. Recommend to change NovoLog vial to Non-Preferred and insulin aspart vial to Preferred.
 - 15. Recommend to change NovoLog Mix vial to Non-Preferred and insulin aspart 70/30 vial to Preferred.
 - 16. Recommend to change NovoLog FlexPen to Non-Preferred and insulin aspart FlexPen to Preferred.
 - 17. Recommend to change NovoLog PenFill to Non-Preferred and insulin aspart PenFill to Preferred.
 - 18. Recommend to change NovoLog Mix FlexPen to Non-Preferred and insulin aspart protamine FlexPen to Preferred.
 - 19. Recommend to change Trulicity to Preferred with Conditions.
 - 20. Recommend to change Ozempic to Non-Preferred with Conditions.
 - 21. Recommend to change Baqsimi to Preferred with a step through a preferred reconstitution product.
 - 22. Recommend to change Invokana to Preferred.
 - 23. Recommend to change Invokamet to Preferred.

24. Recommend to change Ciprodex to Preferred (remove age edit).
25. Recommend to change Evamist to Preferred.
26. Recommend to change Nivestym to Preferred with Conditions.
27. Recommend to change Ziextenzo to Preferred with Conditions.
28. Recommend to change Fulphila to Preferred with Conditions.
29. Recommend to change Ruconest to Non-Preferred.
30. Recommend to change Ilevro to Non-Preferred.
31. Recommend to change Nevanac to Preferred.
32. Recommend to change Methylin oral solution to Non-Preferred with Conditions.
33. Recommend to change Concerta to Preferred with Conditions (co-preferred with generic).
34. Recommend to change methylphenidate er capsules (cd) to Preferred with Conditions.
35. Recommend to change methylphenidate er 10mg tablets to Preferred with Conditions.
36. Recommend to change Quillivant XR to Non-Preferred with Conditions.
37. Recommend to change methylphenidate er capsules (1a) to Preferred with Conditions
38. Recommend to change Nuvessa to Preferred

Heidi Price-Eastman motioned to accept the recommendations for lines 14-20, and Chuck Wadle seconded. Kevin de Regnier abstained due to his conflict of interest as explained above, but all other members were in favor. Kevin de Regnier then motioned to accept all remaining recommendations, and Kellen Ludvigson seconded. The decision was unanimous.

VIII. Newly Released Drugs (Dr. Biczak): All following recommendations (with numbering as provided on agenda attachment 4) were made to maximize cost savings to the program unless otherwise noted. Dr. Biczak reviewed the new drugs, and the recommendations were as follows:

1. Bafiertam- Recommend status on the PDL as Non-Preferred with Conditions
2. Enspryng- Recommend status on the PDL as Non-Preferred
3. Evrysdi- Recommend status on the PDL as Non-Preferred with Conditions
4. Fintepla- Recommend status on the PDL as Non-Preferred
5. Inqovi- Recommend status on the PDL as Non-Recommended with Conditions
6. Kesimpta- Recommend status on the PDL as Non-Preferred with Conditions
7. Ongentys- Recommend status on the PDL as Preferred
8. Onureg- Recommend status on the PDL as Non-Recommended with Conditions
9. Qinlock- Recommend status on the PDL as Non-Recommended with Conditions
10. Retevmo- Recommend status on the PDL as Non-Recommended with Conditions
11. Rukobia- Recommend status on the PDL as Non-Recommended
12. Xcopri- Recommend status on the PDL as Non-Preferred
13. Zeposia- Recommend status on the PDL as Non-Preferred with Conditions

Kellen Ludvigson motioned to accept the recommendations above, and Bruce Alexander seconded. The decision was unanimous.

- IX. Newly Released Generic Drugs (Dr. Biczak): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Ciprofloxacin / Dexamethasone Otic	Non-Preferred
Dimethyl Fumarate	Non-Preferred with Conditions
Efavirenz / Lamivudine / Tenofovir	Non-Preferred
Emtricitabine	Non-Preferred
Tolvaptan	Non-Preferred

Kellen Ludvigson motioned to accept the recommendations above, with the exception of making brand name Tecfidera Non-Preferred with Conditions and changing its generic equivalent dimethyl fumarate to Preferred with Conditions rather than the recommendation as listed. Bruce Alexander seconded, and all members were in favor.

- X. New Drug Dosage Forms/Strengths/Combinations/BioSimilar (Dr. Biczak): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
AirDuo Digihaler	Non-Preferred
ArmonAir Digihaler	Non-Preferred
Breztri	Non-Preferred
Cystadrops	Non-Preferred
Hemady	Non-Preferred
Kynmobi	Non-Preferred
Lydexa	Non-Preferred
Ortikos	Non-Preferred
Pantoprazole Oral Packet	Non-Preferred with Conditions
Semglee Vial & Pen	Non-Preferred
Zilxi	Non-Preferred with Conditions

Kellen Ludvigson motioned to accept the recommendations above, with the exception of Semglee. Bruce Alexander seconded, and the decision was unanimous. Kellen Ludvigson then motioned to accept the Semglee recommendation, with Heidi Price-Eastman seconding, and Kevin de Regnier abstaining due to his conflict of interest. All other members were in favor.

A motion was made by Kellen Ludvigson to adjourn the meeting. It was seconded by Kevin de Regnier, and all in attendance approved. The meeting adjourned at 12:10 p.m. The next scheduled meeting is tentatively set for April 15, 2021.